Cargando…

Early intervention in the management of pulmonary arterial hypertension: clinical and economic outcomes

Pulmonary arterial hypertension (PAH) has a high morbidity rate and is fatal if left untreated. Increasing evidence supports early intervention, possibly with initial combination therapy. PAH-specific pharmaceuticals, however, are expensive and may have serious adverse effects, particularly when use...

Descripción completa

Detalles Bibliográficos
Autores principales:	Burger, Charles D, Ghandour, Mohamedanwar, Padmanabhan Menon, Divya, Helmi, Haytham, Benza, Raymond L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5703162/ https://www.ncbi.nlm.nih.gov/pubmed/29200882 http://dx.doi.org/10.2147/CEOR.S119117

Ejemplares similares

Psychosocial and Financial Burden of Therapy in USA Patients with Pulmonary Arterial Hypertension
por: Helgeson, Scott A., et al.
Publicado: (2020)

The Evolution of Risk Assessment in Pulmonary Arterial Hypertension
por: Murthy, Sandhya, et al.
Publicado: (2021)

Data on clinical and economic burden associated with pulmonary arterial hypertension related hospitalizations in the United States
por: Chaturvedi, Abhishek, et al.
Publicado: (2020)

Risk assessment in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
por: Humbert, Marc, et al.
Publicado: (2019)

Safety and efficacy of transitioning from the combination of bosentan and sildenafil to alternative therapy in patients with pulmonary arterial hypertension
por: Verlinden, Nathan J., et al.
Publicado: (2020)

Transitioning from parenteral treprostinil to inhaled treprostinil in patients with pulmonary arterial hypertension
por: Raina, Amresh, et al.
Publicado: (2013)

Pulmonary vasodilators: beyond the bounds of pulmonary arterial hypertension therapy in COVID-19
por: Franco, Veronica, et al.
Publicado: (2020)

Association between cytokines and functional, hemodynamic parameters, and clinical outcomes in pulmonary arterial hypertension
por: Joshi, Aditya A., et al.
Publicado: (2018)

Replacing a phosphodiesterase-5 inhibitor with riociguat in patients with connective tissue disease-associated pulmonary arterial hypertension: a case series
por: Raina, Amresh, et al.
Publicado: (2017)

Riociguat and the right ventricle in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
por: Benza, Raymond L., et al.
Publicado: (2022)

Risk assessment in patients with pulmonary arterial hypertension in the era of COVID 19 pandemic and the telehealth revolution: State of the art review
por: Wesley Milks, Michael, et al.
Publicado: (2021)

The economic burden of pulmonary arterial hypertension in Spain
por: Zozaya, Néboa, et al.
Publicado: (2022)

INSPIRE: Safety and tolerability of inhaled Yutrepia (treprostinil) in pulmonary arterial hypertension (PAH)
por: Hill, Nicholas S., et al.
Publicado: (2022)

Risk assessment in patients with functional class II pulmonary arterial hypertension: Comparison of physician gestalt with ESC/ERS and the REVEAL 2.0 risk score
por: Sahay, Sandeep, et al.
Publicado: (2020)

Bosentan-based, treat-to-target therapy in patients with pulmonary arterial hypertension: results from the COMPASS-3 study
por: Benza, Raymond L., et al.
Publicado: (2017)

Phosphodiesterase type 5 inhibitor to riociguat transition is associated with hemodynamic and symptomatic improvement in pulmonary hypertension
por: Davey, Ryan, et al.
Publicado: (2017)

MicroCT analysis of vascular morphometry: a comparison of right lung lobes in the SUGEN/hypoxic rat model of pulmonary arterial hypertension
por: Faight, Erin M., et al.
Publicado: (2017)

Unique Predictors of Mortality in Patients With Pulmonary Arterial Hypertension Associated With Systemic Sclerosis in the REVEAL Registry
por: Chung, Lorinda, et al.
Publicado: (2014)

Safety and efficacy of RT234 vardenafil inhalation powder on exercise parameters in pulmonary arterial hypertension: phase II, dose-escalation study design
por: Benza, Raymond L., et al.
Publicado: (2022)

The Role of Using Red-Topped - Non-Additive-Containing - Collecting Tube in Diagnosing Pseudohyperkalemia in Chronic Lymphocytic Leukemia
por: Abdulrahim, Ahmed, et al.
Publicado: (2021)

A Rare Case Report of Ruptured Cyst Presenting With Acute Meningitis in an Untreated Neurocysticercosis
por: Shereef, Hammam, et al.
Publicado: (2021)

Prognostication in Pulmonary Arterial Hypertension with Submaximal Exercise Testing
por: Khatri, Vinod, et al.
Publicado: (2015)

Management of Pulmonary Arterial Hypertension
por: Mayeux, Jennalyn D., et al.
Publicado: (2020)

A Rare Case of Small Bowel Obstruction Secondary to Pelvic Inflammatory Disease
por: Ahmed, Ahmed K, et al.
Publicado: (2021)

Disseminated Nocardiosis in a Renal Transplant Recipient
por: Ghandour, Mohamedanwar, et al.
Publicado: (2021)

Economic evaluation of sildenafil for the treatment of pulmonary arterial hypertension in Indonesia
por: Lilyasari, Oktavia, et al.
Publicado: (2019)

Novel composite clinical endpoints and risk scores used in clinical trials in pulmonary arterial hypertension
por: Sitbon, Olivier, et al.
Publicado: (2020)

Computational Simulator Models and Invasive Hemodynamic Monitoring as Tools for Precision Medicine in Pulmonary Arterial Hypertension
por: Manzi, Giovanna, et al.
Publicado: (2021)

LGE in pulmonary hypertension predicts clinical events
por: Soma, Siva, et al.
Publicado: (2011)

Facemasks and Walk Distance in Pulmonary Arterial Hypertension Patients
por: Helgeson, Scott A., et al.
Publicado: (2021)

Rapid Transition from Inhaled Iloprost to Inhaled Treprostinil in Patients with Pulmonary Arterial Hypertension
por: Bourge, Robert C, et al.
Publicado: (2013)

Pulmonary Arterial Stiffness: An Early and Pervasive Driver of Pulmonary Arterial Hypertension
por: Sun, Wei, et al.
Publicado: (2018)

Discontinuation of Intermittent Hemodialysis in HIV-Associated Nephropathy Following Initiation of Antiretroviral Therapy
por: Ghandour, Mohamedanwar, et al.
Publicado: (2021)

Diagnosis and Management of Pulmonary Arterial Hypertension
por: Houtchens, Jeanne, et al.
Publicado: (2011)

Advances in the management of pulmonary arterial hypertension
por: Deshwal, Himanshu, et al.
Publicado: (2021)

Diagnosis and management of pulmonary arterial hypertension
por: Cullivan, Sarah, et al.
Publicado: (2022)

Interventional and Surgical Treatments for Pulmonary Arterial Hypertension
por: Stącel, Tomasz, et al.
Publicado: (2021)

The economic burden of pulmonary arterial hypertension (PAH) in the US on payers and patients
por: Sikirica, Mirko, et al.
Publicado: (2014)

The economic burden of systemic sclerosis related pulmonary arterial hypertension in Australia
por: Morrisroe, Kathleen, et al.
Publicado: (2019)

Pulmonary rehabilitation and exercise in pulmonary arterial hypertension: An underutilized intervention
por: Sahni, Sonu, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_nkb7t5eofhlrk7kf25nv7rges6